Patent application number | Description | Published |
20140302059 | COMPOSITIONS AND METHODS FOR CANCER AND CANCER STEM CELL DETECTION AND ELIMINATION - In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor. In alternative embodiments, the invention provides compositions and methods for measuring or determining, or predicting, chronic myelogenous leukemia (CML) progression, Leukemic Stem Cell (LSC) generation and/or tyrosine kinase inhibitor resistance. In alternative embodiments, the invention provides compositions and methods for determining or measuring the effectiveness of a treatment, a drug, a therapy or a diet for eliminating, killing or reducing the amounts of a leukemic stem cell (LSC) or cells. | 10-09-2014 |
Patent application number | Description | Published |
20080201646 | Tab Order Mapping of User Interfaces - An approach is provided to display a common display page on a variety of display devices using the item's tab order property to determine the display order. Controls that are displayed on a display device typically have a tab order. When a window that has controls is displayed, the cursor is typically placed at the control with the lowest (i.e., first) tab order. When the user presses the tab key, the cursor moves to the control corresponding to the next lowest tab order. This allows the designer to design a single window (or panel) that is displayed differently on constrained devices. However, even though the window is displayed differently, using tab order mapping maintains a consistent visible proximity between controls despite the type of display device being used by the user. | 08-21-2008 |
20100218030 | INTERACTIVE PROBLEM RESOLUTION PRESENTED WITHIN THE CONTEXT OF MAJOR OBSERVABLE APPLICATION BEHAVIORS - A system, method, and article of manufacture are disclosed for monitoring and resolving problems detected in the application stack. The application stack may include multiple, interpedently application components which collectively provide a unified service. An interactive problem resolution program may monitor and assist users in troubleshooting an application stack installed on a separate computer system. Generally, when a problem in the application stack is detected, the IPR Program may alert users to the problem and provide information about the problem to guide users in taking steps to correct the problem. | 08-26-2010 |
20110055619 | SYNCHRONIZING PROBLEM RESOLUTION TASK STATUS USING AWARENESS OF CURRENT STATE AND TRANSACTION HISTORY - Systems, methods and articles of manufacture are disclosed for synchronizing a transaction profile with a resolution status of a problem experienced by an application. The problem may be detected for the application. A transaction profile may be retrieved for the detected problem. The transaction profile may include a sequence of transactions to be performed on the system to remedy the open problem. Transactions occurring on the system may be monitored, and an instance of the transaction profile may be updated accordingly to create a synchronized transaction profile. | 03-03-2011 |
20140344666 | WEBPAGE DISPLAY SYSTEM LEVERAGING OSGI - A method, system, and/or computer program product generate and present a webpage on a user interface. A request for an initial page view of an initial page is transmitted from a client computer to a server-side layout manager in a server that is OSGi enabled. The client computer receives a copy of the initial page view, a client-side rendering engine, and a client-side layout manager from the server. The client-side layout manager parses out client-side controllers from the client-side layout manager to determine which views are to be pre-fetched before generating a requested webpage. The client-side layout manager invokes the client-side rendering engine to pre-fetch and cache selected views of particular webpages. The client-side layout manager then invokes the client-side rendering engine to build and render the requested webpage from the initial page view and one or more of the cached views. | 11-20-2014 |
Patent application number | Description | Published |
20090176763 | Azaindoles useful as inhibitors of JAK and other protein kinases - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 07-09-2009 |
20100144739 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF - The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders. | 06-10-2010 |
20110020377 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 01-27-2011 |
20120258958 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 10-11-2012 |
20130345197 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 12-26-2013 |
20140249138 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 09-04-2014 |
Patent application number | Description | Published |
20080311079 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 12-18-2008 |
20100330109 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 12-30-2010 |
20110104115 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 05-05-2011 |
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
20130116169 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 05-09-2013 |
20130190289 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - A compound is represented by Structural Formula (I): | 07-25-2013 |
20140031277 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 01-30-2014 |
20140142119 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 05-22-2014 |
20140296201 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 10-02-2014 |